首页> 外国专利> METHOD FOR EARLY DIAGNOSTICS OF NEONATAL SEPSIS

METHOD FOR EARLY DIAGNOSTICS OF NEONATAL SEPSIS

机译:新生儿脓毒症早期诊断方法

摘要

FIELD: medicine.;SUBSTANCE: invention relates to medicine, namely to neonatology, and can be used for early diagnosis of neonatal sepsis. Biological material is taken from a newborn. Then, using the enzyme-linked immunosorbent assay technology, the level of the following inflammatory markers is determined in the biological material: Presepsin (S-CD14), Interleukin-18 (IL-18) and Serum amyloid-A (SAA). At a concentration of Interleukin-18 over 60 pg/ml, and Presepsin and Serum amyloid-A (SAA) over 600 pg/ml, the onset of a septic process is diagnosed. To determine S-CD14, IL-18 and SAA, blood can be used as a biological material, and urine can be used to determine IL-18 and SAA. Determination of markers can be carried out immediately after birth and then 24 and 72 hours after birth. To assess the effectiveness of treatment, the determination of markers of inflammation can be carried out in the course of the ongoing antibiotic therapy.;EFFECT: method provides the possibility of increasing the accuracy and sensitivity of diagnosis, reducing the time of the study, as well as reducing the number of false positive results obtained by determining S-CD14, IL-18 and SAA in the blood or urine of a newborn by enzyme immunoassay.;5 cl, 1 ex
机译:田地:医学。物质:发明涉及医学,即新生儿学,可用于新生儿败血症的早期诊断。生物材料取自新生儿。然后,使用酶联免疫吸附测定技术,在生物材料中测定以下炎症标记的水平:PREPSIN(S-CD14),白细胞介素-18(IL-18)和血清淀粉样蛋白-A(SAA)。在60pg / ml超过60pg / ml的白细胞介素-18的浓度下,并寄生和血清淀粉样蛋白-a(SAA)超过600pg / ml,诊断了抑制化学过程的发作。为了确定S-CD14,IL-18和SAA,血液可用作生物材料,尿液可用于确定IL-18和SAA。标记物的测定可以在出生后立即进行,然后出生后24小时和72小时进行。为了评估治疗的有效性,可以在持续的抗生素治疗过程中进行炎症标志物。;效果:方法提供了提高诊断的准确性和敏感性的可能性,减少了研究的时间,如以及通过酶免疫测定法测定S-CD14,IL-18和SAA通过测定S-CD14,IL-18和SAA获得的假阳性结果的数量。; 5 CL,1 EX

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号